Contact by melanoma cells causes malignant transformation of human epithelial-like stem cells via alpha V integrin activation of transforming growth factor β1 signaling

Experimental Biology and Medicine

Volumn 236, Issue 3, 2011, Pages 352-365

  Sun, Hongyu ^a,b   Hu, Kaimeng ^a   Wu, Minjuan ^a   Xiong, Jun ^a   Yuan, Li ^c   Tang, Ying ^a   Yang, Yongji ^a   Liu, Houqi ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b No 60 Hospital of PLA   (China)

^c SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

3D culture model; Epithelial mesenchymal transition; Human epithelial like stem cells; Integrin alpha V; Melanoma formation; TGF 1 signaling pathway

Indexed keywords

CD51 ANTIGEN; DIMETHYLBENZ[A]ANTHRACENE; NERVE CELL ADHESION MOLECULE; SMAD PROTEIN; TRANSFORMING GROWTH FACTOR BETA1; UVOMORULIN; VIMENTIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL; CARCINOGENICITY; CELL INTERACTION; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CELL TRANSFORMATION; COCULTURE; COLONY FORMATION; EPITHELIAL MESENCHYMAL TRANSITION; EPITHELIUM CELL; HUMAN; HUMAN CELL; HUMAN EPITHELIUM LIKE STEM CELL; IN VITRO STUDY; INTRACELLULAR SIGNALING; MELANOMA CELL; MOUSE; NONHUMAN; PROTEIN EXPRESSION; SOMATIC MUTATION; STEM CELL; TUMOR MICROENVIRONMENT; TUMOR XENOGRAFT;

9,10-DIMETHYL-1,2-BENZANTHRACENE; CELL TRANSFORMATION, NEOPLASTIC; CELLS, CULTURED; COCULTURE TECHNIQUES; HUMANS; INTEGRIN ALPHAV; MELANOMA; MUTAGENS; SIGNAL TRANSDUCTION; STEM CELLS; TRANSFORMING GROWTH FACTOR BETA1;

EID: 79953227424     PISSN: 15353702     EISSN: 15353699     Source Type: Journal    
DOI: 10.1258/ebm.2010.010106     Document Type: Article

References (53)

1. Soto AM, Sonnenschein C. The somatic mutation theory of cancer: growing problems with the paradigm? BioEssays 2004;26:1097-107
2. Weaver VM, Gilbert P. Watch thy neighbor: cancer is a communal affair. J Cell Sci 2004;117:1287-90 (Pubitemid 38559806)
3. Osawa M, Hanada K, Hamada H, Nakauchi H. Long-term lymphohematopoietic reconstitution by a single CD34-low/negative hematopoietic stem cell. Science 2006;273:242-5
4. Reynolds BA, Weiss S. Clonal and population analyses demonstrate that an EGF-responsive mammalian embryonic CNS precursor is a stem cell. Dev Biol 1996;175:1-13 (Pubitemid 26150042)
5. Kim CF, Jackson EL, Woolfenden AE, Lawrence S, Babar I, Vogel S, Crowley D, Bronson RT, Jacks T. Identification of bronchioalveolar stem cells in normal lung and lung cancer. Cell 2005;121:823-35 (Pubitemid 40806415)
6. Lam JS, Reiter RE. Stem cells in prostate and prostate cancer development. Urol Oncol 2006;24:131-40 (Pubitemid 43340170)
7. Allinen M, Beroukhim R, Cai L, Brennan C, Lahti-Domenici J, Huang H, Porter D, Chin L, Richardson A, Schnitt S, Sellers WR, Polyak K. Molecular characterization of the tumor microenvironment in breast cancer. Cancer Cell 2004;6:17-32 (Pubitemid 38903159)
8. Bissell MJ, LaBarge MA. Context, tissue plasticity, and cancer: are tumor stem cells also regulated by the microenvironment? Cancer Cell 2005;7:17-23
9. Tang C, Ang BT, Pervaiz S. Cancer stem cell: target for anti-cancer therapy. FASEB J 2007;21:3777-85 (Pubitemid 350232335)
10. Vogelstein B, Kinzler KW. The multistep nature of cancer. Trends Genet 1993;9:138-41 (Pubitemid 23098782)
11. Calabrese P, Tavare S, Shibata D. Pretumor progression: clonal evolution of human stem cell populations. Am J Pathol 2004;164:1337-46 (Pubitemid 38387799)
12. Li L, Xie T. Stem cell niche: structure and function. Annu Rev Cell Dev Biol 2005;21:605-31 (Pubitemid 41740648)
13. Kim KM, Calabrese P, Tavare S, Shibata D. Enhanced stem cell survival in familial adenomatous polyposis. Am J Pathol 2004;164:1369-77 (Pubitemid 38387802)
14. Gao JX. Cancer stem cells: the lessons from precancerous stem cells. J Cell Mol Med 2008;12:67-96
15. Rubin H. Microenvironmental regulation of the initiated cell. Adv Cancer Res 2003;90:1-62 (Pubitemid 37549220)
16. Bhowmick Neilson EG, Moses HL. Stromal fibroblasts in cancer initiation and progression. Nature 2004;432:332-7 (Pubitemid 39551661)
17. Kuperwasser T, Chavarria M, Magrane G, Gray JW, Carey L, Richardson A, Weinberg RA. Reconstruction of functionally normal and malignant human breast tissues in mice. Proc Natl Acad Sci USA 2004;101:4966-71 (Pubitemid 38469186)
18. Olumi AF, Grossfeld GD, Hayward SW, Carroll PR, Tlsty TD, Cunha GR. Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium. Cancer Res 1999;59:5002-11 (Pubitemid 29472907)
19. Abbott DE, Bailey CM, Postovit LM, Seftor EA, Margaryan N, Seftor RE, Hendrix MJ. The epigenetic influence of tumor and embryonic microenvironments: how different are they? Cancer Microenviron 2008;1:13-21
20. Postovit LM, Seftor EA, Seftor REB, Hendrix MJC. A 3-D model to study the epigenetic effects induced by the microenvironment of human embryonic stem cells. Stem Cells 2006;24:501-5 (Pubitemid 44464753)
21. Seftor EA, Brown KM, Chin L, Kirschmann DA, Wheaton WW, Protopopov A, Feng B, Balagurunathan Y, Trent JM, Nickoloff BJ, Seftor RE, Hendrix MJ. Epigenetic transdifferentiation of normal melanocytes by a metastatic melanoma microenvironment. Cancer Res 2005;65:10164-9 (Pubitemid 41743704)
22. Zhou JX, Chen SY, Liu WM, Cao YJ, Duan EK, Enrichment and identification of human 'fetal' epidermal stem cells. Hum Reprod 2004;19:968-74
23. Jones PH, Watt FM. Separation of human epidermal stem cells from transit amplifying cells on the basis of differences in integrin function and expression. Cell 1993;73:713-24 (Pubitemid 23159010)
24. Kopper L, Hajdu M. Tumor stem cells. Pathol Oncol Res 2004;10:69-74
25. Kang Y, Massague A. Epithelial-mesenchymal transitions: twist in development and metastasis. Cell 2004;118:277-9 (Pubitemid 39061108)
26. Maeda M, Johnson KR, Wheelock MJ. Cadherin switching: essential for behavioral but not morphological changes during an epithelium-to-mesenchyme transition. J Cell Sci 2005;118:873-87 (Pubitemid 40484880)
27. Bates RC, Mercurio AM. The epithelial-mesenchymal transition (EMT) and colorectal cancer progression. Cancer Biol Ther 2005;4: 365-70 (Pubitemid 41351251)
28. Zeisberg M, Maeshima Y, Mosterman B, Kalluri R. Extracellular matrix microenvironment regulates migratory behavior of activated tubular epithelial cells. Am J Pathol 2002;160:2001-8 (Pubitemid 34663393)
29. Thiery JP. Epithelial-mesenchymal transitions in development and pathologies. Curr Opin Cell Biol 2003;15:740-6 (Pubitemid 37487967)
30. Valdes F, Alvarez AM, Locascio A. The epithelial mesenchymal transition confers resistance to the apoptotic effects of transforming growth factor Beta in fetal rat hepatocytes. Mol Cancer Res 2002;1: 68-78 (Pubitemid 36330212)
31. Kleeff J, Ishiwata-Maruyama H, Friess H, Truong P, Büchler MW, Falb D, Korc M. The TGF-beta signaling inhibitor Smad7 enhances tumorigenicity in pancreatic cancel. Oncogene 1999;18:5363-72 (Pubitemid 29469224)
32. Gorelik L, Flavell RA. Eradication of tumors through the blockade of transforming growth factor-beta signaling in TGF-beta. Nat Med 2001;7:1118-22 (Pubitemid 33010019)
33. Chen W, Wahl SM. TGF-β: receptors, signaling pathways and autoimmunity. In: Altman A, ed. Signal Transduction Pathways in Autoimmunity. Curr Dir Autoimmun 2002;5:62-91
34. Li MO, Wan YY, Sanjabi S, Robertson AK, Flavell RA. Transforming growth factor-β regulation of immune responses. Annu Rev Immunol 2006;24:99-146
35. Yingling JM, Blanchard KL, Sawyer JS. Development of TGF-β signalling inhibitors for cancer. Nat Rev Drug Discov 2004;3:1011-22 (Pubitemid 39642364)
36. Bierie B, Moses HL. Tumor microenvironment: TGF-β: the molecular Jekyll and Hyde of cancer. Nat Rev Cancer 2006;6:506-20
37. Akhurst RJ, Derynk R. TGF-β signaling in cancer-a double-edged sword. Trends Cell Biol 2001;11:S44-51
38. Muraoka RS, Dumont N, Ritter CA, Dugger TC, Brantley DM, Chen J, Roebuck LR, Ryan S, Gotwals PJ, Koteliansky V, Arteaga CL. Blockade of TGF-β inhibits mammary tumor cell viability, migration, and metastasis. J Clin Invest 2002;109:1551-9 (Pubitemid 34663517)
39. Yang YA, Dukhanina O, Tang B, Mamura M, Letterio JJ, MacGregor J, Patel SC, Khozin S, Liu ZY, Green J, Anver MR, Merlino G, Wakefield LM. Lifetime exposure to a soluble TGF-β antagonist protects mice against metastasis without adverse side effects. J Clin Invest 2002;109:1607-15 (Pubitemid 34663523)
40. Muraoka-Cook RS, Shin I, Yi JY, Easterly E, Barcellos-Hoff MH, Yingling JM, Zent R, Arteaga CL. Activated type I TGF-β receptor kinase enhances the survival of mammary epithelial cells and accelerates tumor progression. Oncogene 2006;25:3408-23 (Pubitemid 43877044)
41. Ao M, Williams K, Bhowmick NA, Hayward SW. Transforming growth factor-{β} promotes invasion in tumorigenic but not in nontumorigenic human prostatic epithelial cells. Cancer Res 2006;66:8007-16 (Pubitemid 44299165)
42. Halder SK, Beauchamp RD, Datta PK. A specific inhibitor of TGF-β receptor kinase, SB-431542, as a potent antitumor agent for human cancers. Neoplasia 2005;7:509-21 (Pubitemid 40791869)
43. Akhurst RJ. Large- and small-molecule inhibitors of transforming growth factor-β signaling. Curr Opin Invest Drugs 2006;7:513-21 (Pubitemid 43891029)
44. McCarty JH, Barry M, Crowley D, Bronson RT, Lacy-Hulbert A, Hynes RO. Genetic ablation of av integrins in epithelial cells of the eyelid skin and conjunctiva leads to squamous cell carcinoma. Am J Pathol 2008;172:1740-7 (Pubitemid 351793364)
45. Watt FM. Role of integrins in regulating epidermal adhesion, growth and differentiation. EMBO J 2002;21:3919-26 (Pubitemid 34857425)
46. Felding-Habermann B, Mueller BM, Romerdahl CA, Cheresh DA. Involvement of integrin alpha V gene expression in human melanoma tumorigenicity. J Clin Invest 1992;89:2018-22
47. Mitjans F, Sander D, Adán J, Sutter A, Martinez JM, Jäggle CS, Moyano JM, Kreysch HG, Piulats J, Goodman SL. An anti-αv-integrin antibody that blocks integrin function inhibits the development of a human melanoma in nude mice. J Cell Sci 1995;108:2825-38
48. Petitclerc E, Strömblad S, von Schalscha TL, Mitjans F, Piulats J, Montgomery AM, Cheresh DA, Brooks PC. Integrin alpha(v)beta3 promotes M21 melanoma growth in human skin by regulating tumor cell survival. Cancer Res 1999;11:2724-30
49. Stupack DG, Puente XS, Boutsaboualoy S, Storgard CM, Cheresh DA. Apoptosis of adherent cells by recruitment of caspase-8 to unligated integrins. J Cell Biol 2001;3:459-70 (Pubitemid 34289336)
50. Stupack DG, Teitz T, Potter MD, Mikolon D, Houghton PJ, Kidd VJ, Lahti JM, Cheresh DA. Potentiation of neuroblastoma metastasis by loss of caspase-8. Nature 2006;7072:95-9 (Pubitemid 43053635)
51. He J-M, Wang F-C, Qi H-B, Li Y, Liang H-J. Down-regulation of av integrin by retroviral delivery of small interfering RNA reduces multicellular resistance of HT29. Cancer Lett 2009;284:182-8
52. Van Aarsen LA, Leone DR, Ho S, Dolinski BM, McCoon PE, LePage DJ, Kelly R, Heaney G, Rayhorn P, Reid C, Simon KJ, Horan GS, Tao N, Gardner HA, Skelly MM, Gown AM, Thomas GJ, Weinreb PH, Fawell SE, Violette SM. Antibody-mediated blockade of integrin alpha v beta 6 inhibits tumor progression in vivo by a transforming growth factor-beta-regulated mechanism. Cancer Res 2008;68:561-70 (Pubitemid 351380085)
53. Munger JS, Huang X, Kawakatsu H, Griffiths MJ, Dalton SL, Wu J, Pittet JF, Kaminski N, Garat C, Matthay MA, Rifkin DB, Sheppard D. The integrin αvβ6 binds and activates latent TGFβ1: a mechanism for regul ating pulmonary inflammation and fibrosis. Cell 1999;96:319-28 (Pubitemid 29077586)